Tilman Speicher

Kirrberger Str. 100, Geb. 50
Homburg, SL 66421, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

Real-world evaluation of [177Lu]Lu-PSMA-617 RLT in post-taxane mCRPC: feasibility and safety of individualized treatment in a challenging cohort.

Real-world evaluation of [177Lu]Lu-PSMA-617 RLT in post-taxane mCRPC: feasibility and safety of individualized treatment in a challenging cohort.

Journal: European journal of nuclear medicine and molecular imaging

Published: April 09, 2026

FDG PET/CT imaging in recurrent papillary thyroid cancer: does BRAF mutation status matter?

FDG PET/CT imaging in recurrent papillary thyroid cancer: does BRAF mutation status matter?

Journal: The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...

Published: March 30, 2026

Automated PROMISE V2 Scoring from PSMA PET/CT Reports Using Large Language Models: A Comparative Evaluation of Prompt Design and Model Performance.

Automated PROMISE V2 Scoring from PSMA PET/CT Reports Using Large Language Models: A Comparative Evaluation of Prompt Design and Model Performance.

Journal: Current oncology (Toronto, Ont.)

Published: March 27, 2026

Zirconium-89-based PSMA PET/CT with delayed imaging for early detection of biochemical recurrence in prostate cancer patients with PSA ≤ 0.2 ng/mL: A feasibility study.

Zirconium-89-based PSMA PET/CT with delayed imaging for early detection of biochemical recurrence in prostate cancer patients with PSA ≤ 0.2 ng/mL: A feasibility study.

Journal: European journal of nuclear medicine and molecular imaging

Published: January 24, 2026

Auger Emitting [161Tb]Tb-PSMA-617 Radioligand Therapy in mCRPC with Peritoneal Carcinomatosis.

Auger Emitting [161Tb]Tb-PSMA-617 Radioligand Therapy in mCRPC with Peritoneal Carcinomatosis.

Journal: Nuclear medicine and molecular imaging

Published: October 15, 2025

Comparison of mCRPC [177Lu]Lu-PSMA-617 radioligand therapy with and without concurrent enzalutamide medication in a real-world setting.

Comparison of mCRPC [177Lu]Lu-PSMA-617 radioligand therapy with and without concurrent enzalutamide medication in a real-world setting.

Journal: European journal of nuclear medicine and molecular imaging

Published: September 12, 2025

Outcome and Safety of Radioligand Therapy With [ 161 Tb]Tb-PSMA-617 After Re-Progression in mCRPC Patients Previously Treated With [ 177 Lu]Lu-PSMA-617.

Outcome and Safety of Radioligand Therapy With [ 161 Tb]Tb-PSMA-617 After Re-Progression in mCRPC Patients Previously Treated With [ 177 Lu]Lu-PSMA-617.

Journal: Clinical nuclear medicine

Published: August 19, 2025

Tolerability of PSMA radioligand therapy in metastatic prostate cancer patients with baseline mild to moderate leukopenia.

Tolerability of PSMA radioligand therapy in metastatic prostate cancer patients with baseline mild to moderate leukopenia.

Journal: EJNMMI research

Published: May 01, 2025

Pilot experience of [161Tb]Tb-PSMA-617 RLT in mCRPC patients after conventional PSMA RLT within a prospective registry.

Pilot experience of [161Tb]Tb-PSMA-617 RLT in mCRPC patients after conventional PSMA RLT within a prospective registry.

Journal: Theranostics

Published: April 16, 2025

Advancing patient education in PRRT through large language models: challenges and potential.

Advancing patient education in PRRT through large language models: challenges and potential.

Journal: American journal of nuclear medicine and molecular imaging

Published: April 13, 2025

Expanding the scope of PSMA-RLT: evaluating treatment in challenging mCRPC patients with poor performance status (ECOG 3).

Expanding the scope of PSMA-RLT: evaluating treatment in challenging mCRPC patients with poor performance status (ECOG 3).

Journal: European journal of nuclear medicine and molecular imaging

Published: March 12, 2025

[18F]FDG PET/CT of Langerhans Cell Histiocytosis with Vertebra Plana.

[18F]FDG PET/CT of Langerhans Cell Histiocytosis with Vertebra Plana.

Journal: Diagnostics (Basel, Switzerland)

Published: March 06, 2025

Showing 1-12 of 24

Last Updated: 09/26/2026